3.1 The Institute has published technology appraisals on the use of the following drugs for breast cancer: temozolomide, capecitabine, taxanes, trastuzumab and vinorelbine. For further information, visit our website.
3.2 The Institute issued cancer service guidance called 'Improving Outcomes in Breast Cancer' in August 2002 and is developing a clinical guideline on breast cancer, called 'Breast cancer: diagnosis and treatment'. The expected date of issue of this guideline is September 2007 [Now published as 'Breast cancer (early and locally advanced): diagnosis and treatment'].
The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.
NICE has produced information on this procedure for patients and carers ('Understanding NICE guidance'). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.